http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Fri, 22 May 2026 07:01:09 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Equity+Offerings/BioStem+Technologies+raises+%242.5+million+from+first+institutional+investor/26538443.html <p>BioStem Technologies Inc. (OTC: BSEM) announced it has secured $2.5 million in a private placement with its first institutional investor. The regenerative medicine company entered into a securities purchase agreement for the sale of 746,269 shares of common stock at $3.35 per share.</p> <p>The company plans to use the net proceeds for working capital and general corporate purposes. The transaction is expected to close on or about May 22, 2026, subject to customary closing conditions.</p> <p>"This transaction marks continued progress in the execution of our capital markets strategy, and, together with the previously announced debt retirement, strengthens our balance sheet," said Jason http://www.streetinsider.com/Equity+Offerings/BioStem+Technologies+raises+%242.5+million+from+first+institutional+investor/26538443.html Fri, 22 May 2026 07:01:09 -0400 A.50113823 A.50208593 BSEM O.00303771 O.00725546 http://www.streetinsider.com/Equity+Offerings/BioStem+Technologies+raises+%242.5+million+from+first+institutional+investor/26538443.html <p>BioStem Technologies Inc. (OTC: BSEM) announced it has secured $2.5 million in a private placement with its first institutional investor. The regenerative medicine company entered into a securities purchase agreement for the sale of 746,269 shares of common stock at $3.35 per share.</p> <p>The company plans to use the net proceeds for working capital and general corporate purposes. The transaction is expected to close on or about May 22, 2026, subject to customary closing conditions.</p> <p>"This transaction marks continued progress in the execution of our capital markets strategy, and, together with the previously announced debt retirement, strengthens our balance sheet," said Jason http://www.streetinsider.com/Equity+Offerings/BioStem+Technologies+raises+%242.5+million+from+first+institutional+investor/26538443.html Fri, 22 May 2026 07:01:09 -0400 A.50113823 A.50208593 BSEM O.00303771 O.00725546 http://www.streetinsider.com/Equity+Offerings/BioStem+Technologies+raises+%242.5+million+from+first+institutional+investor/26538443.html <p>BioStem Technologies Inc. (OTC: BSEM) announced it has secured $2.5 million in a private placement with its first institutional investor. The regenerative medicine company entered into a securities purchase agreement for the sale of 746,269 shares of common stock at $3.35 per share.</p> <p>The company plans to use the net proceeds for working capital and general corporate purposes. The transaction is expected to close on or about May 22, 2026, subject to customary closing conditions.</p> <p>"This transaction marks continued progress in the execution of our capital markets strategy, and, together with the previously announced debt retirement, strengthens our balance sheet," said Jason http://www.streetinsider.com/Equity+Offerings/BioStem+Technologies+raises+%242.5+million+from+first+institutional+investor/26538443.html Fri, 22 May 2026 07:01:09 -0400 A.50113823 A.50208593 BSEM O.00303771 O.00725546 http://www.streetinsider.com/Equity+Offerings/BioStem+Technologies+raises+%242.5+million+from+first+institutional+investor/26538443.html <p>BioStem Technologies Inc. (OTC: BSEM) announced it has secured $2.5 million in a private placement with its first institutional investor. The regenerative medicine company entered into a securities purchase agreement for the sale of 746,269 shares of common stock at $3.35 per share.</p> <p>The company plans to use the net proceeds for working capital and general corporate purposes. The transaction is expected to close on or about May 22, 2026, subject to customary closing conditions.</p> <p>"This transaction marks continued progress in the execution of our capital markets strategy, and, together with the previously announced debt retirement, strengthens our balance sheet," said Jason http://www.streetinsider.com/Equity+Offerings/BioStem+Technologies+raises+%242.5+million+from+first+institutional+investor/26538443.html Fri, 22 May 2026 07:01:09 -0400 A.50113823 A.50208593 BSEM O.00303771 O.00725546 http://www.streetinsider.com/Equity+Offerings/BioStem+Technologies+raises+%242.5+million+from+first+institutional+investor/26538443.html <p>BioStem Technologies Inc. (OTC: BSEM) announced it has secured $2.5 million in a private placement with its first institutional investor. The regenerative medicine company entered into a securities purchase agreement for the sale of 746,269 shares of common stock at $3.35 per share.</p> <p>The company plans to use the net proceeds for working capital and general corporate purposes. The transaction is expected to close on or about May 22, 2026, subject to customary closing conditions.</p> <p>"This transaction marks continued progress in the execution of our capital markets strategy, and, together with the previously announced debt retirement, strengthens our balance sheet," said Jason http://www.streetinsider.com/Equity+Offerings/BioStem+Technologies+raises+%242.5+million+from+first+institutional+investor/26538443.html Fri, 22 May 2026 07:01:09 -0400 A.50113823 A.50208593 BSEM O.00303771 O.00725546 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html <p align="justify">POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FbWDj0rGl3aD_QAR2JeO5ILicGukH2J2Ony1bnqwxMiBgcXfbnI5cGAnI04jGQNGlqk79zlE47TQJOdcBtIwqGTaLsoelsZgxEMytHluJr-gdsMVm8fGnzNfDZ5U_ooWeypccrJbMt_X_Nh8KhulMxgaA7zz04OOd8v03sjjU1tKUDiwf9qvr0SUn_h55RDtW80qzgUa_jQmi-T3Xg5XEM5NMWa1r4wxyMLr6E9vYovRXdJuJS_ZoBzTEa0GhS5GqeiYm5uMltwZnzXZ6CrSOCzVlxhOhiCsFiLrj4emcCn4axu_1OwZfQpvgNZMBuN69y2ugm1RWvMyfuEEe2FMKbuHsn6tPNACmv9Q1FvWcTNxvrA_FKOIJr_i-cZivw_yj7aKgTj8bTIMdtNkwj5y9xocuBRwcCYgponopCT4VfloEmkdxVOMGlLVqndxkxaa9vFhb6wTnXeOzQrBM8CqYfNM9--b3d3A7R-H3pLGeqdDSU9URFOevPacvGmx84yU_6wZoqGewqfHl2NGAY_yDpCTMs8MfrwMFTjAYEerFqhh6DPBkv0LNKe-74XzlY2ruvk5_JjCs0B1dtLNFnMIuidtPNbGCop33vk2GimCC82eM-3V5TjQ65VMb-3QiFhXqClGA4RKpsozaZT1JL-a9EKGjBO-QeWwA0yZarfugp8OD27-6eRhWmWfUSpM_p8gs0Q1__Al-1FkPbC3arH2d7LMuol3a08loxmhiTDXP6KiwdhEiKLqRGWpBPuxe1BjI6Q9BShYhBmM4ZXzl4WR-aFpyNZlD1L_j91YGUVnjJD54XAQ3tYMW15dCMCmfnEDPYzAzn_B9CwdtNjKJUncgVyPnPwaFnOnHpgrlRed0V-2_IacdK16Qg9a10wO7dz9" rel="nofollow" target="_blank">BioStem Technologies Inc.</a>(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggregate gross proceeds of approximately $2.5 million. The Company expects to use the net proceeds from the offering for working capital and general corporate purposes.</p> http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html Fri, 22 May 2026 07:00:00 -0400 A.50113823 A.50208593 BSEM O.00303771 O.00725546 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html <p align="justify">POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FbWDj0rGl3aD_QAR2JeO5ILicGukH2J2Ony1bnqwxMiBgcXfbnI5cGAnI04jGQNGlqk79zlE47TQJOdcBtIwqGTaLsoelsZgxEMytHluJr-gdsMVm8fGnzNfDZ5U_ooWeypccrJbMt_X_Nh8KhulMxgaA7zz04OOd8v03sjjU1tKUDiwf9qvr0SUn_h55RDtW80qzgUa_jQmi-T3Xg5XEM5NMWa1r4wxyMLr6E9vYovRXdJuJS_ZoBzTEa0GhS5GqeiYm5uMltwZnzXZ6CrSOCzVlxhOhiCsFiLrj4emcCn4axu_1OwZfQpvgNZMBuN69y2ugm1RWvMyfuEEe2FMKbuHsn6tPNACmv9Q1FvWcTNxvrA_FKOIJr_i-cZivw_yj7aKgTj8bTIMdtNkwj5y9xocuBRwcCYgponopCT4VfloEmkdxVOMGlLVqndxkxaa9vFhb6wTnXeOzQrBM8CqYfNM9--b3d3A7R-H3pLGeqdDSU9URFOevPacvGmx84yU_6wZoqGewqfHl2NGAY_yDpCTMs8MfrwMFTjAYEerFqhh6DPBkv0LNKe-74XzlY2ruvk5_JjCs0B1dtLNFnMIuidtPNbGCop33vk2GimCC82eM-3V5TjQ65VMb-3QiFhXqClGA4RKpsozaZT1JL-a9EKGjBO-QeWwA0yZarfugp8OD27-6eRhWmWfUSpM_p8gs0Q1__Al-1FkPbC3arH2d7LMuol3a08loxmhiTDXP6KiwdhEiKLqRGWpBPuxe1BjI6Q9BShYhBmM4ZXzl4WR-aFpyNZlD1L_j91YGUVnjJD54XAQ3tYMW15dCMCmfnEDPYzAzn_B9CwdtNjKJUncgVyPnPwaFnOnHpgrlRed0V-2_IacdK16Qg9a10wO7dz9" rel="nofollow" target="_blank">BioStem Technologies Inc.</a>(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggregate gross proceeds of approximately $2.5 million. The Company expects to use the net proceeds from the offering for working capital and general corporate purposes.</p> http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html Fri, 22 May 2026 07:00:00 -0400 A.50113823 A.50208593 BSEM O.00303771 O.00725546 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html <p align="justify">POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FbWDj0rGl3aD_QAR2JeO5ILicGukH2J2Ony1bnqwxMiBgcXfbnI5cGAnI04jGQNGlqk79zlE47TQJOdcBtIwqGTaLsoelsZgxEMytHluJr-gdsMVm8fGnzNfDZ5U_ooWeypccrJbMt_X_Nh8KhulMxgaA7zz04OOd8v03sjjU1tKUDiwf9qvr0SUn_h55RDtW80qzgUa_jQmi-T3Xg5XEM5NMWa1r4wxyMLr6E9vYovRXdJuJS_ZoBzTEa0GhS5GqeiYm5uMltwZnzXZ6CrSOCzVlxhOhiCsFiLrj4emcCn4axu_1OwZfQpvgNZMBuN69y2ugm1RWvMyfuEEe2FMKbuHsn6tPNACmv9Q1FvWcTNxvrA_FKOIJr_i-cZivw_yj7aKgTj8bTIMdtNkwj5y9xocuBRwcCYgponopCT4VfloEmkdxVOMGlLVqndxkxaa9vFhb6wTnXeOzQrBM8CqYfNM9--b3d3A7R-H3pLGeqdDSU9URFOevPacvGmx84yU_6wZoqGewqfHl2NGAY_yDpCTMs8MfrwMFTjAYEerFqhh6DPBkv0LNKe-74XzlY2ruvk5_JjCs0B1dtLNFnMIuidtPNbGCop33vk2GimCC82eM-3V5TjQ65VMb-3QiFhXqClGA4RKpsozaZT1JL-a9EKGjBO-QeWwA0yZarfugp8OD27-6eRhWmWfUSpM_p8gs0Q1__Al-1FkPbC3arH2d7LMuol3a08loxmhiTDXP6KiwdhEiKLqRGWpBPuxe1BjI6Q9BShYhBmM4ZXzl4WR-aFpyNZlD1L_j91YGUVnjJD54XAQ3tYMW15dCMCmfnEDPYzAzn_B9CwdtNjKJUncgVyPnPwaFnOnHpgrlRed0V-2_IacdK16Qg9a10wO7dz9" rel="nofollow" target="_blank">BioStem Technologies Inc.</a>(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggregate gross proceeds of approximately $2.5 million. The Company expects to use the net proceeds from the offering for working capital and general corporate purposes.</p> http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html Fri, 22 May 2026 07:00:00 -0400 A.50113823 A.50208593 BSEM O.00303771 O.00725546 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html <p align="justify">POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FbWDj0rGl3aD_QAR2JeO5ILicGukH2J2Ony1bnqwxMiBgcXfbnI5cGAnI04jGQNGlqk79zlE47TQJOdcBtIwqGTaLsoelsZgxEMytHluJr-gdsMVm8fGnzNfDZ5U_ooWeypccrJbMt_X_Nh8KhulMxgaA7zz04OOd8v03sjjU1tKUDiwf9qvr0SUn_h55RDtW80qzgUa_jQmi-T3Xg5XEM5NMWa1r4wxyMLr6E9vYovRXdJuJS_ZoBzTEa0GhS5GqeiYm5uMltwZnzXZ6CrSOCzVlxhOhiCsFiLrj4emcCn4axu_1OwZfQpvgNZMBuN69y2ugm1RWvMyfuEEe2FMKbuHsn6tPNACmv9Q1FvWcTNxvrA_FKOIJr_i-cZivw_yj7aKgTj8bTIMdtNkwj5y9xocuBRwcCYgponopCT4VfloEmkdxVOMGlLVqndxkxaa9vFhb6wTnXeOzQrBM8CqYfNM9--b3d3A7R-H3pLGeqdDSU9URFOevPacvGmx84yU_6wZoqGewqfHl2NGAY_yDpCTMs8MfrwMFTjAYEerFqhh6DPBkv0LNKe-74XzlY2ruvk5_JjCs0B1dtLNFnMIuidtPNbGCop33vk2GimCC82eM-3V5TjQ65VMb-3QiFhXqClGA4RKpsozaZT1JL-a9EKGjBO-QeWwA0yZarfugp8OD27-6eRhWmWfUSpM_p8gs0Q1__Al-1FkPbC3arH2d7LMuol3a08loxmhiTDXP6KiwdhEiKLqRGWpBPuxe1BjI6Q9BShYhBmM4ZXzl4WR-aFpyNZlD1L_j91YGUVnjJD54XAQ3tYMW15dCMCmfnEDPYzAzn_B9CwdtNjKJUncgVyPnPwaFnOnHpgrlRed0V-2_IacdK16Qg9a10wO7dz9" rel="nofollow" target="_blank">BioStem Technologies Inc.</a>(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggregate gross proceeds of approximately $2.5 million. The Company expects to use the net proceeds from the offering for working capital and general corporate purposes.</p> http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html Fri, 22 May 2026 07:00:00 -0400 A.50113823 A.50208593 BSEM O.00303771 O.00725546 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html <p align="justify">POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FbWDj0rGl3aD_QAR2JeO5ILicGukH2J2Ony1bnqwxMiBgcXfbnI5cGAnI04jGQNGlqk79zlE47TQJOdcBtIwqGTaLsoelsZgxEMytHluJr-gdsMVm8fGnzNfDZ5U_ooWeypccrJbMt_X_Nh8KhulMxgaA7zz04OOd8v03sjjU1tKUDiwf9qvr0SUn_h55RDtW80qzgUa_jQmi-T3Xg5XEM5NMWa1r4wxyMLr6E9vYovRXdJuJS_ZoBzTEa0GhS5GqeiYm5uMltwZnzXZ6CrSOCzVlxhOhiCsFiLrj4emcCn4axu_1OwZfQpvgNZMBuN69y2ugm1RWvMyfuEEe2FMKbuHsn6tPNACmv9Q1FvWcTNxvrA_FKOIJr_i-cZivw_yj7aKgTj8bTIMdtNkwj5y9xocuBRwcCYgponopCT4VfloEmkdxVOMGlLVqndxkxaa9vFhb6wTnXeOzQrBM8CqYfNM9--b3d3A7R-H3pLGeqdDSU9URFOevPacvGmx84yU_6wZoqGewqfHl2NGAY_yDpCTMs8MfrwMFTjAYEerFqhh6DPBkv0LNKe-74XzlY2ruvk5_JjCs0B1dtLNFnMIuidtPNbGCop33vk2GimCC82eM-3V5TjQ65VMb-3QiFhXqClGA4RKpsozaZT1JL-a9EKGjBO-QeWwA0yZarfugp8OD27-6eRhWmWfUSpM_p8gs0Q1__Al-1FkPbC3arH2d7LMuol3a08loxmhiTDXP6KiwdhEiKLqRGWpBPuxe1BjI6Q9BShYhBmM4ZXzl4WR-aFpyNZlD1L_j91YGUVnjJD54XAQ3tYMW15dCMCmfnEDPYzAzn_B9CwdtNjKJUncgVyPnPwaFnOnHpgrlRed0V-2_IacdK16Qg9a10wO7dz9" rel="nofollow" target="_blank">BioStem Technologies Inc.</a>(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggregate gross proceeds of approximately $2.5 million. The Company expects to use the net proceeds from the offering for working capital and general corporate purposes.</p> http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html Fri, 22 May 2026 07:00:00 -0400 A.50113823 A.50208593 BSEM O.00303771 O.00725546 http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html <p align="justify">POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FbWDj0rGl3aD_QAR2JeO5ILicGukH2J2Ony1bnqwxMiBgcXfbnI5cGAnI04jGQNGlqk79zlE47TQJOdcBtIwqGTaLsoelsZgxEMytHluJr-gdsMVm8fGnzNfDZ5U_ooWeypccrJbMt_X_Nh8KhulMxgaA7zz04OOd8v03sjjU1tKUDiwf9qvr0SUn_h55RDtW80qzgUa_jQmi-T3Xg5XEM5NMWa1r4wxyMLr6E9vYovRXdJuJS_ZoBzTEa0GhS5GqeiYm5uMltwZnzXZ6CrSOCzVlxhOhiCsFiLrj4emcCn4axu_1OwZfQpvgNZMBuN69y2ugm1RWvMyfuEEe2FMKbuHsn6tPNACmv9Q1FvWcTNxvrA_FKOIJr_i-cZivw_yj7aKgTj8bTIMdtNkwj5y9xocuBRwcCYgponopCT4VfloEmkdxVOMGlLVqndxkxaa9vFhb6wTnXeOzQrBM8CqYfNM9--b3d3A7R-H3pLGeqdDSU9URFOevPacvGmx84yU_6wZoqGewqfHl2NGAY_yDpCTMs8MfrwMFTjAYEerFqhh6DPBkv0LNKe-74XzlY2ruvk5_JjCs0B1dtLNFnMIuidtPNbGCop33vk2GimCC82eM-3V5TjQ65VMb-3QiFhXqClGA4RKpsozaZT1JL-a9EKGjBO-QeWwA0yZarfugp8OD27-6eRhWmWfUSpM_p8gs0Q1__Al-1FkPbC3arH2d7LMuol3a08loxmhiTDXP6KiwdhEiKLqRGWpBPuxe1BjI6Q9BShYhBmM4ZXzl4WR-aFpyNZlD1L_j91YGUVnjJD54XAQ3tYMW15dCMCmfnEDPYzAzn_B9CwdtNjKJUncgVyPnPwaFnOnHpgrlRed0V-2_IacdK16Qg9a10wO7dz9" rel="nofollow" target="_blank">BioStem Technologies Inc.</a>(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggregate gross proceeds of approximately $2.5 million. The Company expects to use the net proceeds from the offering for working capital and general corporate purposes.</p> http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html Fri, 22 May 2026 07:00:00 -0400 A.50113823 A.50208593 BSEM O.00303771 O.00725546 http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html <p align="justify">POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FbWDj0rGl3aD_QAR2JeO5ILicGukH2J2Ony1bnqwxMiBgcXfbnI5cGAnI04jGQNGlqk79zlE47TQJOdcBtIwqGTaLsoelsZgxEMytHluJr-gdsMVm8fGnzNfDZ5U_ooWeypccrJbMt_X_Nh8KhulMxgaA7zz04OOd8v03sjjU1tKUDiwf9qvr0SUn_h55RDtW80qzgUa_jQmi-T3Xg5XEM5NMWa1r4wxyMLr6E9vYovRXdJuJS_ZoBzTEa0GhS5GqeiYm5uMltwZnzXZ6CrSOCzVlxhOhiCsFiLrj4emcCn4axu_1OwZfQpvgNZMBuN69y2ugm1RWvMyfuEEe2FMKbuHsn6tPNACmv9Q1FvWcTNxvrA_FKOIJr_i-cZivw_yj7aKgTj8bTIMdtNkwj5y9xocuBRwcCYgponopCT4VfloEmkdxVOMGlLVqndxkxaa9vFhb6wTnXeOzQrBM8CqYfNM9--b3d3A7R-H3pLGeqdDSU9URFOevPacvGmx84yU_6wZoqGewqfHl2NGAY_yDpCTMs8MfrwMFTjAYEerFqhh6DPBkv0LNKe-74XzlY2ruvk5_JjCs0B1dtLNFnMIuidtPNbGCop33vk2GimCC82eM-3V5TjQ65VMb-3QiFhXqClGA4RKpsozaZT1JL-a9EKGjBO-QeWwA0yZarfugp8OD27-6eRhWmWfUSpM_p8gs0Q1__Al-1FkPbC3arH2d7LMuol3a08loxmhiTDXP6KiwdhEiKLqRGWpBPuxe1BjI6Q9BShYhBmM4ZXzl4WR-aFpyNZlD1L_j91YGUVnjJD54XAQ3tYMW15dCMCmfnEDPYzAzn_B9CwdtNjKJUncgVyPnPwaFnOnHpgrlRed0V-2_IacdK16Qg9a10wO7dz9" rel="nofollow" target="_blank">BioStem Technologies Inc.</a>(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggregate gross proceeds of approximately $2.5 million. The Company expects to use the net proceeds from the offering for working capital and general corporate purposes.</p> http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html Fri, 22 May 2026 07:00:00 -0400 A.50113823 A.50208593 BSEM O.00303771 O.00725546 http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html <p align="justify">POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FbWDj0rGl3aD_QAR2JeO5ILicGukH2J2Ony1bnqwxMiBgcXfbnI5cGAnI04jGQNGlqk79zlE47TQJOdcBtIwqGTaLsoelsZgxEMytHluJr-gdsMVm8fGnzNfDZ5U_ooWeypccrJbMt_X_Nh8KhulMxgaA7zz04OOd8v03sjjU1tKUDiwf9qvr0SUn_h55RDtW80qzgUa_jQmi-T3Xg5XEM5NMWa1r4wxyMLr6E9vYovRXdJuJS_ZoBzTEa0GhS5GqeiYm5uMltwZnzXZ6CrSOCzVlxhOhiCsFiLrj4emcCn4axu_1OwZfQpvgNZMBuN69y2ugm1RWvMyfuEEe2FMKbuHsn6tPNACmv9Q1FvWcTNxvrA_FKOIJr_i-cZivw_yj7aKgTj8bTIMdtNkwj5y9xocuBRwcCYgponopCT4VfloEmkdxVOMGlLVqndxkxaa9vFhb6wTnXeOzQrBM8CqYfNM9--b3d3A7R-H3pLGeqdDSU9URFOevPacvGmx84yU_6wZoqGewqfHl2NGAY_yDpCTMs8MfrwMFTjAYEerFqhh6DPBkv0LNKe-74XzlY2ruvk5_JjCs0B1dtLNFnMIuidtPNbGCop33vk2GimCC82eM-3V5TjQ65VMb-3QiFhXqClGA4RKpsozaZT1JL-a9EKGjBO-QeWwA0yZarfugp8OD27-6eRhWmWfUSpM_p8gs0Q1__Al-1FkPbC3arH2d7LMuol3a08loxmhiTDXP6KiwdhEiKLqRGWpBPuxe1BjI6Q9BShYhBmM4ZXzl4WR-aFpyNZlD1L_j91YGUVnjJD54XAQ3tYMW15dCMCmfnEDPYzAzn_B9CwdtNjKJUncgVyPnPwaFnOnHpgrlRed0V-2_IacdK16Qg9a10wO7dz9" rel="nofollow" target="_blank">BioStem Technologies Inc.</a>(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggregate gross proceeds of approximately $2.5 million. The Company expects to use the net proceeds from the offering for working capital and general corporate purposes.</p> http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html Fri, 22 May 2026 07:00:00 -0400 A.50113823 A.50208593 BSEM O.00303771 O.00725546 http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html <p align="justify">POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FbWDj0rGl3aD_QAR2JeO5ILicGukH2J2Ony1bnqwxMiBgcXfbnI5cGAnI04jGQNGlqk79zlE47TQJOdcBtIwqGTaLsoelsZgxEMytHluJr-gdsMVm8fGnzNfDZ5U_ooWeypccrJbMt_X_Nh8KhulMxgaA7zz04OOd8v03sjjU1tKUDiwf9qvr0SUn_h55RDtW80qzgUa_jQmi-T3Xg5XEM5NMWa1r4wxyMLr6E9vYovRXdJuJS_ZoBzTEa0GhS5GqeiYm5uMltwZnzXZ6CrSOCzVlxhOhiCsFiLrj4emcCn4axu_1OwZfQpvgNZMBuN69y2ugm1RWvMyfuEEe2FMKbuHsn6tPNACmv9Q1FvWcTNxvrA_FKOIJr_i-cZivw_yj7aKgTj8bTIMdtNkwj5y9xocuBRwcCYgponopCT4VfloEmkdxVOMGlLVqndxkxaa9vFhb6wTnXeOzQrBM8CqYfNM9--b3d3A7R-H3pLGeqdDSU9URFOevPacvGmx84yU_6wZoqGewqfHl2NGAY_yDpCTMs8MfrwMFTjAYEerFqhh6DPBkv0LNKe-74XzlY2ruvk5_JjCs0B1dtLNFnMIuidtPNbGCop33vk2GimCC82eM-3V5TjQ65VMb-3QiFhXqClGA4RKpsozaZT1JL-a9EKGjBO-QeWwA0yZarfugp8OD27-6eRhWmWfUSpM_p8gs0Q1__Al-1FkPbC3arH2d7LMuol3a08loxmhiTDXP6KiwdhEiKLqRGWpBPuxe1BjI6Q9BShYhBmM4ZXzl4WR-aFpyNZlD1L_j91YGUVnjJD54XAQ3tYMW15dCMCmfnEDPYzAzn_B9CwdtNjKJUncgVyPnPwaFnOnHpgrlRed0V-2_IacdK16Qg9a10wO7dz9" rel="nofollow" target="_blank">BioStem Technologies Inc.</a>(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggregate gross proceeds of approximately $2.5 million. The Company expects to use the net proceeds from the offering for working capital and general corporate purposes.</p> http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html Fri, 22 May 2026 07:00:00 -0400 A.50113823 A.50208593 BSEM O.00303771 O.00725546 http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html <p align="justify">POMPANO BEACH, Fla., May 22, 2026 (GLOBE NEWSWIRE) -- <a target="_blank" href="https://www.globenewswire.com/Tracker?data=FbWDj0rGl3aD_QAR2JeO5ILicGukH2J2Ony1bnqwxMiBgcXfbnI5cGAnI04jGQNGlqk79zlE47TQJOdcBtIwqGTaLsoelsZgxEMytHluJr-gdsMVm8fGnzNfDZ5U_ooWeypccrJbMt_X_Nh8KhulMxgaA7zz04OOd8v03sjjU1tKUDiwf9qvr0SUn_h55RDtW80qzgUa_jQmi-T3Xg5XEM5NMWa1r4wxyMLr6E9vYovRXdJuJS_ZoBzTEa0GhS5GqeiYm5uMltwZnzXZ6CrSOCzVlxhOhiCsFiLrj4emcCn4axu_1OwZfQpvgNZMBuN69y2ugm1RWvMyfuEEe2FMKbuHsn6tPNACmv9Q1FvWcTNxvrA_FKOIJr_i-cZivw_yj7aKgTj8bTIMdtNkwj5y9xocuBRwcCYgponopCT4VfloEmkdxVOMGlLVqndxkxaa9vFhb6wTnXeOzQrBM8CqYfNM9--b3d3A7R-H3pLGeqdDSU9URFOevPacvGmx84yU_6wZoqGewqfHl2NGAY_yDpCTMs8MfrwMFTjAYEerFqhh6DPBkv0LNKe-74XzlY2ruvk5_JjCs0B1dtLNFnMIuidtPNbGCop33vk2GimCC82eM-3V5TjQ65VMb-3QiFhXqClGA4RKpsozaZT1JL-a9EKGjBO-QeWwA0yZarfugp8OD27-6eRhWmWfUSpM_p8gs0Q1__Al-1FkPbC3arH2d7LMuol3a08loxmhiTDXP6KiwdhEiKLqRGWpBPuxe1BjI6Q9BShYhBmM4ZXzl4WR-aFpyNZlD1L_j91YGUVnjJD54XAQ3tYMW15dCMCmfnEDPYzAzn_B9CwdtNjKJUncgVyPnPwaFnOnHpgrlRed0V-2_IacdK16Qg9a10wO7dz9" rel="nofollow" target="_blank">BioStem Technologies Inc.</a>(OTC: BSEM), a leading regenerative medicine company focused on the development, manufacturing, and commercialization of perinatal tissue allograft products, today announced it has entered into a securities purchase agreement (the “Securities Purchase Agreement”) with its first institutional investor for the purchase and sale of 746,269 shares of common stock at a price of $3.35 per share for aggregate gross proceeds of approximately $2.5 million. The Company expects to use the net proceeds from the offering for working capital and general corporate purposes.</p> http://www.streetinsider.com/Globe+Newswire/BioStem+Technologies+Announces+%242.5+Million+Private+Placement+Financing+with+its+First+Institutional+Investor/26538431.html Fri, 22 May 2026 07:00:00 -0400 A.50113823 A.50208593 BSEM O.00303771 O.00725546 http://www.streetinsider.com/Corporate+News/BioStem+Technologies+receives+patent+approvals+for+placental+allografts/26525770.html <p>BioStem Technologies announced that the United States Patent and Trademark Office issued Notices of Allowance for four divisional U.S. design patent applications related to fenestrated human placental allograft technologies. The European Patent Office also granted the company a patent covering sterile human placental allografts and manufacturing methods.</p> <p>The four U.S. design patents (Nos. 30/010,024, 30/010,026, 30/010,032, and 30/010,034) cover different fenestrated human placental allograft designs intended for wound care and surgical applications. The designs focus on fluid management, conformability, and tissue integration characteristics.</p> <p>The European patent (EP4442316A2) covers sterile human placental allografts and processing methods designed to preserve structural integrity and growth http://www.streetinsider.com/Corporate+News/BioStem+Technologies+receives+patent+approvals+for+placental+allografts/26525770.html Wed, 20 May 2026 09:01:12 -0400 A.03718595 A.50113823 BSEM O.00725546 O.04906507 http://www.streetinsider.com/Corporate+News/BioStem+Technologies+receives+patent+approvals+for+placental+allografts/26525770.html <p>BioStem Technologies announced that the United States Patent and Trademark Office issued Notices of Allowance for four divisional U.S. design patent applications related to fenestrated human placental allograft technologies. The European Patent Office also granted the company a patent covering sterile human placental allografts and manufacturing methods.</p> <p>The four U.S. design patents (Nos. 30/010,024, 30/010,026, 30/010,032, and 30/010,034) cover different fenestrated human placental allograft designs intended for wound care and surgical applications. The designs focus on fluid management, conformability, and tissue integration characteristics.</p> <p>The European patent (EP4442316A2) covers sterile human placental allografts and processing methods designed to preserve structural integrity and growth http://www.streetinsider.com/Corporate+News/BioStem+Technologies+receives+patent+approvals+for+placental+allografts/26525770.html Wed, 20 May 2026 09:01:12 -0400 A.03718595 A.50113823 BSEM O.00725546 O.04906507 http://www.streetinsider.com/Corporate+News/BioStem+Technologies+receives+patent+approvals+for+placental+allografts/26525770.html <p>BioStem Technologies announced that the United States Patent and Trademark Office issued Notices of Allowance for four divisional U.S. design patent applications related to fenestrated human placental allograft technologies. The European Patent Office also granted the company a patent covering sterile human placental allografts and manufacturing methods.</p> <p>The four U.S. design patents (Nos. 30/010,024, 30/010,026, 30/010,032, and 30/010,034) cover different fenestrated human placental allograft designs intended for wound care and surgical applications. The designs focus on fluid management, conformability, and tissue integration characteristics.</p> <p>The European patent (EP4442316A2) covers sterile human placental allografts and processing methods designed to preserve structural integrity and growth http://www.streetinsider.com/Corporate+News/BioStem+Technologies+receives+patent+approvals+for+placental+allografts/26525770.html Wed, 20 May 2026 09:01:12 -0400 A.03718595 A.50113823 BSEM O.00725546 O.04906507 http://www.streetinsider.com/Corporate+News/BioStem+Technologies+receives+patent+approvals+for+placental+allografts/26525770.html <p>BioStem Technologies announced that the United States Patent and Trademark Office issued Notices of Allowance for four divisional U.S. design patent applications related to fenestrated human placental allograft technologies. The European Patent Office also granted the company a patent covering sterile human placental allografts and manufacturing methods.</p> <p>The four U.S. design patents (Nos. 30/010,024, 30/010,026, 30/010,032, and 30/010,034) cover different fenestrated human placental allograft designs intended for wound care and surgical applications. The designs focus on fluid management, conformability, and tissue integration characteristics.</p> <p>The European patent (EP4442316A2) covers sterile human placental allografts and processing methods designed to preserve structural integrity and growth http://www.streetinsider.com/Corporate+News/BioStem+Technologies+receives+patent+approvals+for+placental+allografts/26525770.html Wed, 20 May 2026 09:01:12 -0400 A.03718595 A.50113823 BSEM O.00725546 O.04906507 http://www.streetinsider.com/Corporate+News/BioStem+Technologies+receives+patent+approvals+for+placental+allografts/26525770.html <p>BioStem Technologies announced that the United States Patent and Trademark Office issued Notices of Allowance for four divisional U.S. design patent applications related to fenestrated human placental allograft technologies. The European Patent Office also granted the company a patent covering sterile human placental allografts and manufacturing methods.</p> <p>The four U.S. design patents (Nos. 30/010,024, 30/010,026, 30/010,032, and 30/010,034) cover different fenestrated human placental allograft designs intended for wound care and surgical applications. The designs focus on fluid management, conformability, and tissue integration characteristics.</p> <p>The European patent (EP4442316A2) covers sterile human placental allografts and processing methods designed to preserve structural integrity and growth http://www.streetinsider.com/Corporate+News/BioStem+Technologies+receives+patent+approvals+for+placental+allografts/26525770.html Wed, 20 May 2026 09:01:12 -0400 A.03718595 A.50113823 BSEM O.00725546 O.04906507 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+Notice+of+Allowance+for+Four+U.S.+Design+Patent+Applications+Covering+Fenestrated+Human+Placental+Allografts+and+One+European+Patent/26525707.html <p>Pompano Beach, FL, May 20, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies®, a leading regenerative medicine company focused on developing and commercializing placental-derived biologics, today announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for four new divisional U.S. design patent applications related to its fenestrated human placental allograft technologies. The European Patent Office also issued BioStem a new patent covering sterile human placental allografts and proprietary manufacturing methods for growth factor-rich placental tissue allografts.</p> <p>No. 30/010,024: FENESTRATED HUMAN PLACENTAL ALLOGRAFT<br/>The patent is directed to fenestrated human placental allograft http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+Notice+of+Allowance+for+Four+U.S.+Design+Patent+Applications+Covering+Fenestrated+Human+Placental+Allografts+and+One+European+Patent/26525707.html Wed, 20 May 2026 09:00:00 -0400 A.03718595 A.50113823 BSEM O.00725546 O.04906507 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+Notice+of+Allowance+for+Four+U.S.+Design+Patent+Applications+Covering+Fenestrated+Human+Placental+Allografts+and+One+European+Patent/26525707.html <p>Pompano Beach, FL, May 20, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies®, a leading regenerative medicine company focused on developing and commercializing placental-derived biologics, today announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for four new divisional U.S. design patent applications related to its fenestrated human placental allograft technologies. The European Patent Office also issued BioStem a new patent covering sterile human placental allografts and proprietary manufacturing methods for growth factor-rich placental tissue allografts.</p> <p>No. 30/010,024: FENESTRATED HUMAN PLACENTAL ALLOGRAFT<br/>The patent is directed to fenestrated human placental allograft http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+Notice+of+Allowance+for+Four+U.S.+Design+Patent+Applications+Covering+Fenestrated+Human+Placental+Allografts+and+One+European+Patent/26525707.html Wed, 20 May 2026 09:00:00 -0400 A.03718595 A.50113823 BSEM O.00725546 O.04906507 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+Notice+of+Allowance+for+Four+U.S.+Design+Patent+Applications+Covering+Fenestrated+Human+Placental+Allografts+and+One+European+Patent/26525707.html <p>Pompano Beach, FL, May 20, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies®, a leading regenerative medicine company focused on developing and commercializing placental-derived biologics, today announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for four new divisional U.S. design patent applications related to its fenestrated human placental allograft technologies. The European Patent Office also issued BioStem a new patent covering sterile human placental allografts and proprietary manufacturing methods for growth factor-rich placental tissue allografts.</p> <p>No. 30/010,024: FENESTRATED HUMAN PLACENTAL ALLOGRAFT<br/>The patent is directed to fenestrated human placental allograft http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+Notice+of+Allowance+for+Four+U.S.+Design+Patent+Applications+Covering+Fenestrated+Human+Placental+Allografts+and+One+European+Patent/26525707.html Wed, 20 May 2026 09:00:00 -0400 A.03718595 A.50113823 BSEM O.00725546 O.04906507 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+Notice+of+Allowance+for+Four+U.S.+Design+Patent+Applications+Covering+Fenestrated+Human+Placental+Allografts+and+One+European+Patent/26525707.html <p>Pompano Beach, FL, May 20, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies®, a leading regenerative medicine company focused on developing and commercializing placental-derived biologics, today announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for four new divisional U.S. design patent applications related to its fenestrated human placental allograft technologies. The European Patent Office also issued BioStem a new patent covering sterile human placental allografts and proprietary manufacturing methods for growth factor-rich placental tissue allografts.</p> <p>No. 30/010,024: FENESTRATED HUMAN PLACENTAL ALLOGRAFT<br/>The patent is directed to fenestrated human placental allograft http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+Notice+of+Allowance+for+Four+U.S.+Design+Patent+Applications+Covering+Fenestrated+Human+Placental+Allografts+and+One+European+Patent/26525707.html Wed, 20 May 2026 09:00:00 -0400 A.03718595 A.50113823 BSEM O.00725546 O.04906507 http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+Notice+of+Allowance+for+Four+U.S.+Design+Patent+Applications+Covering+Fenestrated+Human+Placental+Allografts+and+One+European+Patent/26525707.html <p>Pompano Beach, FL, May 20, 2026 (GLOBE NEWSWIRE) -- BioStem Technologies®, a leading regenerative medicine company focused on developing and commercializing placental-derived biologics, today announced that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for four new divisional U.S. design patent applications related to its fenestrated human placental allograft technologies. The European Patent Office also issued BioStem a new patent covering sterile human placental allografts and proprietary manufacturing methods for growth factor-rich placental tissue allografts.</p> <p>No. 30/010,024: FENESTRATED HUMAN PLACENTAL ALLOGRAFT<br/>The patent is directed to fenestrated human placental allograft http://www.streetinsider.com/Press+Releases/BioStem+Technologies+Announces+Notice+of+Allowance+for+Four+U.S.+Design+Patent+Applications+Covering+Fenestrated+Human+Placental+Allografts+and+One+European+Patent/26525707.html Wed, 20 May 2026 09:00:00 -0400 A.03718595 A.50113823 BSEM O.00725546 O.04906507